Nano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy

Tsai-Mu Cheng; Wong-Jin Chang; Hsiu-Yi Chu; Roberto De Luca; Jens Z. Pedersen; Sandra Incerpi; Zi-Lin Li; Ya-Jung Shih; Hung-Yun Lin; Kuan Wang; Jacqueline Whang-Peng

doi:10.3390/cells10071684

Cells (Jul 2021)

Nano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy

Tsai-Mu Cheng,
Wong-Jin Chang,
Hsiu-Yi Chu,
Roberto De Luca,
Jens Z. Pedersen,
Sandra Incerpi,
Zi-Lin Li,
Ya-Jung Shih,
Hung-Yun Lin,
Kuan Wang,
Jacqueline Whang-Peng

Affiliations

Tsai-Mu Cheng: Graduate Institute for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Wong-Jin Chang: Graduate Institute for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Hsiu-Yi Chu: Graduate Institute for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Roberto De Luca: Department of Neurology, Center for Life Science, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
Jens Z. Pedersen: Department of Biology, University of Rome Tor Vergata, 00133 Rome, Italy
Sandra Incerpi: Department of Sciences, University “Roma Tre”, 00154 Rome, Italy
Zi-Lin Li: Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan
Ya-Jung Shih: Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan
Hung-Yun Lin: Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan
Kuan Wang: Graduate Institute of Nanomedicine and Medical Engineering, College of Medical Engineering, Taipei Medical University, Taipei 11031, Taiwan
Jacqueline Whang-Peng: Graduate Institute for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei 11031, Taiwan

DOI: https://doi.org/10.3390/cells10071684
Journal volume & issue: Vol. 10, no. 7
p. 1684

Abstract

Read online

Integrin αvβ3, a cell surface receptor, participates in signaling transduction pathways in cancer cell proliferation and metastasis. Several ligands bind to integrin αvβ3 to regulate proliferation and metastasis in cancer cells. Crosstalk between the integrin and other signal transduction pathways also plays an important role in modulating cancer proliferation. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) activates the downstream integrin FAK to stimulate biological activities including cancer proliferation and metastasis. Blockage of signals related to integrin αvβ3 was shown to be a promising target for cancer therapies. 3,3′,5,5′-tetraiodothyroacetic acid (tetrac) completely binds to the integrin with the thyroid hormone to suppress cancer proliferation. The (E)-stilbene analog, resveratrol, also binds to integrin αvβ3 to inhibit cancer growth. Recently, nanotechnologies have been used in the biomedical field for detection and therapeutic purposes. In the current review, we show and evaluate the potentiation of the nanomaterial carrier RGD peptide, derivatives of PLGA-tetrac (NDAT), and nanoresveratrol targeting integrin αvβ3 in cancer therapies.

Published in Cells

ISSN: 2073-4409 (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Science: Biology (General): Cytology
Website: https://www.mdpi.com/journal/cells

About the journal

Abstract

Keywords